{"url_path":"/sec/rnxt/8-k/2026-07-02/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1574094/0001493152-26-031662-index.html","accession_number":"0001493152-26-031662","cik":"0001574094","ticker":"RNXT","issuer_name":"RenovoRx, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1574094/0001493152-26-031662-index.html","primary_entity_key":"0001574094","primary_entity_name":"RenovoRx, Inc."},"word_count":293,"has_tables":true,"body_markdown":"** **\n\n**Item\n3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**\n\n \n\nAs\npreviously reported, on December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice\nfrom The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock (the “Common Stock”) had\nfailed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule\n5550(a)(2) (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was initially\nprovided 180 calendar days, or until June 30, 2026, to regain compliance.\n\n \n\nOn\nJuly 1, 2026, the Company received a notification letter from Nasdaq informing the Company that, while the Company has not yet regained\ncompliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar\nday period, or until December 28, 2026 (the “Second Compliance Period”), to regain compliance.\n\n \n\nIf\nat any time during the Second Compliance Period, the closing bid price of the Common Stock is at least $1.00 per share for a minimum\nof 10 consecutive business days, Nasdaq will provide the Company with written confirmation of compliance. If compliance with the Minimum\nBid Price Requirement cannot be demonstrated by December 28, 2026, Nasdaq will provide written notification that the Common Stock\nwill be delisted from Nasdaq. At that time, the Company may appeal Nasdaq’s determination to a Hearings Panel.\n\n \n\n \n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**RenovoRx,\nInc.**\n\n \n \n \n\nDate:\nJuly 2, 2026\nBy:\n*/s/\nShaun R. Bagai*\n\n \nName:\nShaun\nR. Bagai\n\n \nTitle:\nChief\nExecutive Officer"}